awmsg logo



sitagliptin (Januvia®)


Reference No. 1655

Publication date:
25/10/2012


Last review date:
30/09/2016

Appraisal information

sitagliptin (Januvia®) 25 mg film-coated tablet
sitagliptin (Januvia®) 50 mg film-coated tablet


Company: Merck Sharp & Dohme Ltd
BNF category: Endocrine system
NMG meeting date: 10/07/2012
AWMSG meeting date: 12/09/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2912
Ministerial ratification: 25/10/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sitagliptin (Januvia®) 25 and 50 mg tablets are recommended as an option for use within NHS Wales for the improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl ≥ 30 to < 50 ml/min), severe renal impairment (CrCl < 30 ml/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download